BCL2 and acute lymphoblastic leukemia: A recent preclinical study identified Bcl-2 as a key therapeutic target and demonstrated the efficacy of a selective Bcl-2 inhibitor, venetoclax, in hypodiploid ALL, providing a promising treatment strategy to improve the outcomes in this subgroup [29].